Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Aogi, Kenjiro, Watanabe, Kenichi, Kitada, Masahiro, Sangai, Takafumi, Ohtani, Shoichiro, Aruga, Tomoyuki, Kawagichi, Hidetoshi, Fujisawa, Tomomi, Maeda, Shigeto, Morimoto, Takashi, Sato, Nobuaki, Takao, Shintaro, Morita, Satoshi, Masuda, Norikazu, Toi, Masakazu, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496593/
https://www.ncbi.nlm.nih.gov/pubmed/34043103
http://dx.doi.org/10.1007/s10147-021-01940-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496593/
https://www.ncbi.nlm.nih.gov/pubmed/34043103
http://dx.doi.org/10.1007/s10147-021-01940-w

Ejemplares similares